Abstract:The amount of data collected from patients involved in clinical trials is continuously growing. All patient characteristics are potential covariates that could be used to improve clinical trial analysis and power. However, the restricted number of patients in phases I and II studies limits the possible number of covariates included in the analyses. In this paper, we investigate the cost/benefit ratio of including covariates in the analysis of clinical trials. Within this context, we address the long-running question "What is the optimum number of covariates to include in a clinical trial?" To further improve the cost/benefit ratio of covariates, historical data can be leveraged to pre-specify the covariate weights, which can be viewed as the definition of a new composite covariate. We analyze the use of a composite covariate while estimating the treatment effect in small clinical trials. A composite covariate limits the loss of degrees of freedom and the risk of overfitting.
Abstract:This paper presents an original approach for jointly fitting survival times and classifying samples into subgroups. The Coxlogit model is a generalized linear model with a common set of selected features for both tasks. Survival times and class labels are here assumed to be conditioned by a common risk score which depends on those features. Learning is then naturally expressed as maximizing the joint probability of subgroup labels and the ordering of survival events, conditioned to a common weight vector. The model is estimated by minimizing a regularized log-likelihood through a coordinate descent algorithm. Validation on synthetic and breast cancer data shows that the proposed approach outperforms a standard Cox model or logistic regression when both predicting the survival times and classifying new samples into subgroups. It is also better at selecting informative features for both tasks.